Vietnam Health Official Concerned About Safety Of GSK H1N1 Vaccine
This article was originally published in PharmAsia News
A Vietnamese health official said he is concerned about possible cases of anaphylaxis and other severe adverse effects from the 1.2 million doses of H1N1 flu vaccine ordered
You may also be interested in...
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.